Management of Severe Constipation with Bowel Cleanse
For severe constipation, polyethylene glycol (PEG) 17g in 8oz water once or twice daily is the recommended first-line treatment for bowel cleansing, as it has the strongest evidence for efficacy and safety. 1
Initial Assessment and Management
First-Line Treatment
- Polyethylene glycol (PEG): 17g in 8oz water once or twice daily 1
- Can be used as a capful of PEG with 8oz water twice daily for prophylaxis
- Side effects may include abdominal distension, loose stool, flatulence, and nausea
If PEG Alone Is Insufficient
Add stimulant laxatives:
Consider adding:
For Persistent Severe Constipation
Escalation Options
- Increase stimulant laxatives: Bisacodyl 10-15mg, 2-3 times daily 2
- Add osmotic laxatives: Lactulose, magnesium hydroxide, or magnesium citrate 2
- Consider rectal interventions for impaction:
For Opioid-Induced Constipation
If constipation is opioid-induced and unresponsive to standard laxatives:
- Methylnaltrexone: 0.15mg/kg subcutaneously every other day (no more than once daily) 2, 1
- Naldemedine: 0.2mg daily (strong evidence for achieving ≥3 spontaneous bowel movements/week) 1
- Naloxegol: For OIC treatment (moderate-quality evidence) 1
- Lubiprostone: 24mcg twice daily with food (use with caution in patients taking methadone) 1
Non-Pharmacological Interventions
- Increase fluid intake: At least 8 glasses of water daily 1
- Increase dietary fiber: Gradually to 20-25g per day, focusing on soluble fiber 1
- Increase physical activity: Within patient limits 1
- Optimize toileting habits:
- Ensure privacy and comfort
- Use a footstool to elevate knees above hips
- Establish a regular toileting schedule 1
Important Cautions and Contraindications
Safety Concerns
- Avoid sodium phosphate solutions for bowel cleansing, especially in elderly patients or those with kidney disease, as they can cause serious electrolyte abnormalities and acute kidney injury 4
- Avoid fiber supplements in patients with severe constipation or suspected obstruction 1
- Peripherally acting mu-opioid receptor antagonists (PAMORAs) are contraindicated in patients with gastrointestinal perforation risk or mechanical bowel obstruction 1
- Enemas should be used cautiously, especially in elderly patients, due to risk of perforation (1.4% in one study) 3
Monitoring
- Reassess treatment efficacy within 2-4 weeks of initiating treatment 1
- Use the Bowel Function Index to assess severity and monitor response (score ≥30 indicates clinically significant constipation requiring escalation of therapy) 1
- Evaluate for red flag symptoms (rectal bleeding, unintentional weight loss, change in stool caliber, worsening abdominal pain) 1
When to Consider Specialist Referral
- Persistent symptoms despite adequate trial of first and second-line therapies
- Suspicion of defecatory disorders or slow-transit constipation 5
- Need for colonoscopy to rule out structural causes 1
By following this evidence-based approach to managing severe constipation, clinicians can effectively address this common but distressing condition while minimizing risks associated with treatment.